Literature DB >> 30701487

A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.

Tamayo Kato1, Yasuyuki Ushiogi2, Hitoshi Yokoyama3, Shigeo Hara4, Akira Matsunaga5, Eri Muso6,7, Takao Saito8.   

Abstract

A 47-year-old Japanese man with mild proteinuria was treated with an ACE inhibitor and antiplatelet agent for 7 years. However, urinary protein levels increased and renal biopsy was performed. Eight out of 20 glomeruli showed global or segmental sclerosis with foamy changes or bubbles, but with a different appearance to typical foam cells or lipoprotein thrombi. "Spike" formation, as observed in membranous nephropathy (MN), was segmentally detected in methenamine silver-stained sections. In an immunofluorescence study, weak linear patterns for IgG and scanty deposits for C3 were observed in glomeruli, but were not specific for immunogenetic MN. An electron microscopy study showed highly dense deposits in the subepithelial, subendothelial, and mesangial areas, in which microbubbles appeared under a higher magnification. Since this case exhibited hypertriglyceridemia and cholesterolemia with high serum apolipoprotein E (apoE) clinically and homozygous apoE2/2 by apoE phenotype and genotype analyses, apoE2 homozygote glomerulopathy was diagnosed and various lipid-lowering agents, e.g., probucol, fenofibrate, and ezetimibe, were administered. However, renal dysfunction gradually developed and peritoneal dialysis was initiated 11 years after the diagnosis. ApoE Toyonaka (Ser197Cys) and homozygous E2/2 were recently identified by direct DNA sequencing. Therefore, non-immune MN-like lesions may develop with the combination of these apoE mutations.

Entities:  

Keywords:  Apo E2 homozygote glomerulopathy; Apolipoprotein E Toyonaka; Homozygous apolipoprotein E2/2; Lipoprotein glomerulopathy; Membranous nephropathy

Mesh:

Substances:

Year:  2019        PMID: 30701487      PMCID: PMC6450992          DOI: 10.1007/s13730-019-00380-w

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  17 in total

1.  Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

Authors:  S Oikawa; A Matsunaga; T Saito; H Sato; T Seki; K Hoshi; K Hayasaka; H Kotake; H Midorikawa; A Sekikawa; S Hara; K Abe; T Toyota; H Jingami; H Nakamura; J Sasaki
Journal:  J Am Soc Nephrol       Date:  1997-05       Impact factor: 10.121

2.  Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3.

Authors:  V Narayanaswami; S S Szeto; R O Ryan
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

3.  Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions.

Authors:  Jianglei Chen; Qianqian Li; Jianjun Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-22       Impact factor: 11.205

Review 4.  Apolipoproteins: metabolic role and clinical biochemistry applications.

Authors:  Marek H Dominiczak; Muriel J Caslake
Journal:  Ann Clin Biochem       Date:  2011-10-25       Impact factor: 2.057

5.  A monomeric, biologically active, full-length human apolipoprotein E.

Authors:  Yonghong Zhang; Sheeja Vasudevan; Radiya Sojitrawala; Wentao Zhao; Chunxian Cui; Chao Xu; Daping Fan; Yvonne Newhouse; Reeny Balestra; W Gray Jerome; Karl Weisgraber; Qianqian Li; Jianjun Wang
Journal:  Biochemistry       Date:  2007-08-23       Impact factor: 3.162

Review 6.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

7.  Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization.

Authors:  Mark L Segall; Padmaja Dhanasekaran; Faye Baldwin; G M Anantharamaiah; Karl H Weisgraber; Michael C Phillips; Sissel Lund-Katz
Journal:  J Lipid Res       Date:  2002-10       Impact factor: 5.922

Review 8.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

9.  Screening and Evaluation of Deleterious SNPs in APOE Gene of Alzheimer's Disease.

Authors:  Tariq Ahmad Masoodi; Sulaiman A Al Shammari; May N Al-Muammar; Adel A Alhamdan
Journal:  Neurol Res Int       Date:  2012-03-13

10.  Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature.

Authors:  Kunio Kawanishi; Anri Sawada; Ayami Ochi; Takahito Moriyama; Michihiro Mitobe; Toshio Mochizuki; Kazuho Honda; Hideaki Oda; Toshio Nishikawa; Kosaku Nitta
Journal:  Case Rep Nephrol Urol       Date:  2013-11-28
View more
  4 in total

Review 1.  Apolipoprotein E and Atherosclerosis.

Authors:  A D Marais
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.113

Review 2.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

3.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits.

Authors:  Akihiko Koshino; Chikako Takaeda; Takahiro Matsuno; Shinji Kitajima; Yasunori Iwata; Norihiko Sakai; Kiyotaka Nagahama; Yo Niida; Takao Saito; Hitoshi Yokoyama; Takashi Wada
Journal:  Case Rep Nephrol Dial       Date:  2022-06-10

Review 4.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.